Page 3 - Sarah Sheikh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda s Oral Orexin Agonist to Enter Phase 3 Narcolepsy Trials

Takeda announced results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Sarah sheikh mscWakefulness testSarah sheikh

Takeda (TAK) to Rapidly Initiate the First Global Phase 3 Trials of TAK-861

Takeda (TAK) to Rapidly Initiate the First Global Phase 3 Trials of TAK-861
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sarah sheikhGlobal development at takedaWakefulness testEpworth sleepiness scaleWeekly cataplexy rateNeuroscience therapeutic area unitGlobal developmentFiscal year

Positive Data on Oral Orexin Receptor 2 Agonist for Patients with Narcolepsy Type 1

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Elena koundourakisSarah sheikh mscSarah sheikhNeuroscience therapeutic area unitWakefulness testEpworth sleepiness scaleWeekly cataplexy rateSleep disordersNarcolepsy type 1

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSarah sheikhYuko yoneyamaExchange commissionInternational mediaGlobal development at takedaTakeda pharmaceutical company limitedUpcoming scientific congressKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testNeuroscience therapeutic area unitGlobal development

Takeda places $580M bet on AcuraStem s ALS treatments

The ALS program deal could be worth nearly $600 million in upfront and milestone payments for AcuraStem if all clinical, regulatory and commercial milestones are achieved.

United statesSarah sheikhSam alworthTakeda pharmaceuticalsIonis pharmaceuticalsDrug administrationInvestigational new drugAmylyx pharmaceutical relyvrio